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Background: Polyunsaturated fatty acids (PUFAs) are nutrients necessary for life. The liver is the essential metabolic
center, which aids in maintaining health via diverse biological actions. In the present work, a proteomics study was
conducted with an aim to provide new insights into PUFA-regulated hepatic protein expression in apoE-knockout
mice. Additionally, we investigated how n-3 PUFAs influence cytokine-challenge by using HepG2 cells as a model.
Results: Through the proteomic analysis using 2-dimensional electrophoresis and mass spectrometry, we found
that 28, 23, 14, and 28 hepatic proteins were up-regulated at least a two-fold difference in intensity compared with
the control group in mice treated with the docosahexaenoic acid, eicosapentaenoic acid, arachidonic acid, and
linoleic acid, respectively. In contrast, 12 hepatic proteins were down-regulated with a ratio value of less than 0.5
compared to their control counterparts by these four fatty acids. All of the altered proteins were then sorted
according to their biochemical properties related to metabolism, redox stress/inflammation, enzymatic reactions,
and miscellaneous functions. The results provide evidence that PUFAs may act as either pro-inflammatory or
anti-inflammatory agents. Cytokine-challenged HepG2 cells were used to reveal the anti-inflammatory function
of n-3 PUFAs. The results showed that interleukin (IL)-1β combined with IL-6 induced C-reactive protein (CRP)
mRNA expression and its protein secretion by HepG2 cells. The CRP promoter activity was significantly increased
in the IL-6-treated cells, whereas IL-1β alone had no effect. However, IL-1β and IL-6 acted synergistically to further
enhance CRP promoter activities. Furthermore, n-3 PUFAs inhibited nuclear factor-κB (NF-κB) activation and the
phosphorylation of the nuclear signal transducer and activator of transcription 3 (STAT3) during cytokine-induced
CRP production.
Conclusion: This study indicates that PUFAs induced changes in the hepatic protein profile in vivo. Furthermore,
n-3 PUFAs exert their anti-inflammatory properties through differential molecular mechanisms in hepatic cells.
These results provide novel information regarding the roles of PUFAs in the liver at the tissue and cellular levels.
Keywords: Polyunsaturated fatty acids (PUFAs), Proteomics, Inflammation, C-reactive protein (CRP), Nuclear
factor-κB (NF-κB) pathway* Correspondence: whhsheu@vghtc.gov.tw; anchia@ym.edu.tw
†Equal contributors
4Department of Medical Research, Taichung Veterans General Hospital,
Taichung 40354, Taiwan
1Institute of Biochemistry and Molecular Biology, National Yang-Ming
University, No.155, Sec.2, Li-Nong Street, Taipei 11221, Taiwan
Full list of author information is available at the end of the article
© 2015 Huang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Huang et al. Journal of Biomedical Science  (2015) 22:12 Page 2 of 14Background
Dietary n-3 and n-6 polyunsaturated fatty acids (PUFAs)
have multiple physiological functions in humans [1,2].
Ample evidence demonstrated that supplementation
with n-3 PUFAs is able to decrease plasma triacylglycerol
concentration, reduce inflammatory stress, and attenuate
atherosclerotic progression [3-6]. Atherosclerosis is a
cardiometabolic disease and the liver is an essential
metabolic center in animals and humans. However, re-
sponses in terms of hepatic protein expression in ani-
mals or hepatocytes that have been challenged with
different PUFAs are still poorly understood. The eluci-
dation of the regulatory mechanisms involved in these
processes will undoubtedly improve our understanding
for dietary intervention when facing metabolic disor-
ders, inflammation, obesity, carcinogenesis, and coron-
ary artery diseases.
Previous studies have shown that n-3 PUFAs have a
protective role in the prevention of cardiovascular dis-
ease [5-7]. Atherosclerosis is a cardiovascular disease
associated with disorder of inflammatory signaling and
lipid metabolism [8,9]. The liver is directly involved in
the development of the cardiometabolic syndrome,
which links metabolic disorder with cardiovascular
complications [10]. Establishment of an early detection
approach that can slow down or even stop atheroscler-
otic progression is of great interest. In the current study,
we used apoE-knockout (apoE-KO) mice as an animal
model to monitor hepatic protein expression in response
to different PUFAs as a first step using the proteomics ap-
proach. This observation should provide important in-
sights into the regulation of protein expression in the liver
by PUFAs.
Consumption of n-3 PUFAs have been found to sup-
press inflammatory processes, which makes these fatty
acids good candidates for both the prevention and
amelioration of several organ-specific and systemic dis-
eases [11,12]. Inflammation is usually characterized by
cytokine activation. Furthermore, IL-1β and IL-6, either
alone or in combination, influence hepatocyte protein
synthesis and secretion [13,14]. Inflammatory stress has
been suggested to act as a trigger for a complex series of
molecular and biochemical changes that bring hepatic
damages [15]. C-reactive protein (CRP) is a well-known
risk marker for chronic inflammation and this protein is
predominantly produced by hepatocytes [16]. We hy-
pothesized that inflammatory stress-induced CRP secre-
tion by the liver may be influenced by PUFAs. Herein,
we tested the hypothesis that PUFAs may play a role in
modulating the expression and secretion of CRP via dif-
ferent signaling pathways in cytokine-stimulated HepG2
cells, which has been shown with more similarity to hu-
man liver than the other cell lines in comparisons of the
protein expression [17].The aim of this study was to investigate the roles of
PUFAs in the regulation of hepatic protein expres-
sion, in vivo, and in the regulation of the signaling
pathway involved in cytokine-induced CRP expression,
in vitro. First, we elucidated the changes in hepatic
protein expression in apoE-KO mice that had been
treated with the n-3 PUFAs, docosahexaenoic acid
(22:6; DHA) and eicosapentaenoic acid (20:5; EPA), and
the n-6 PUFAs, arachidonic acid (20:4; AA) and linoleic
acid (18:2; LA), by using a proteomic approach. We then
investigated how PUFAs regulate cytokine-induced CRP
expression in HepG2 cells. Signaling events and CRP
gene regulation that occur in IL-β and IL-6-challenged
cells were also investigated. Finally, we propose a model
that aims to describe the mechanisms by which n-3




ApoE-KO mice were originally obtained from Jackson
laboratory (Bar Harbor, ME, USA). Forty 12-week-old-
male mice were bred at the animal center of National
Yang-Ming University. The study followed the Guide for
the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication
No. 85–23, revised 1996) and all experimental proce-
dures were approved by the Animal Care and Utilization
Committee of National Yang-Ming University, Taipei,
Taiwan. After one week on a commercial mouse chow
diet, the mice were randomly allocated to one of five
groups (n = 8). The control group was given normal la-
boratory mouse diet ad libitum and 1.1% ethanol in PBS
(150 mM NaCl, 20 mM sodium phosphate, pH 7.4) by
gavage every day. The other four groups were fed the
same normal diet ad libitum plus 200 mg/kg of DHA,
EPA, AA, or LA in 1.1% ethanol/PBS every day by gav-
age. After 10 weeks on the diet, the mice were fasted
overnight, and their body weight was recorded. The
mice were then euthanized and blood and liver samples
were collected at the end of the experiment. The blood
was centrifuged at 12000 g for 15 min and the plasma
supernatant was then stored at −35°C until analysis.
Liver tissues were harvested, washed with ice-cold iso-
tonic saline, and stored at −80°C until use.
Determination of plasma and hepatic lipid levels
Plasma derived from apoE-KO mice was diluted with
150 mM NaCl, 1 mM EDTA (pH 7.4) so that the OD
measurement and lipid concentrations were brought into
the normal range. The plasma triacylglycerol (TG), total
cholesterol (TC), HDL-cholesterol, and LDL-cholesterol
concentrations were assayed enzymatically using commer-
cial kits (Wako Chemicals, Richmond, VA, USA). Lipids
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method described by Folch et al. [18]. Briefly, total lipids
were extracted from the liver samples by homogenizing
the tissues with 8:4:3 chloroform/methanol/0.9% NaCl
(v/v) to a final dilution of 20-fold the original volume of
the tissue sample. The organic layer was then separated,
evaporated, and reconstituted in chloroform. The values
of TG and TC were normalized against the weight of
the extracted liver.
Proteome analysis
Mouse liver tissue was cut into small pieces and ground
in sample buffer (40 mM Tris–HCl, pH 7.6, 7 M urea,
2 M thiourea, 4% CHAPS, 10 mM 1,4-dithioerythritol,
1 mM EDTA) in the presence of a mixture of protease
inhibitors (1 mM phenylmethanesulfonyl fluoride (PMSF)
and 1 μg/mL of each pepstatin A, chymostatin, leupeptin,
and antipain). Two-dimensional (2-D) gel electrophor-
esis was performed as in a recent proteomics study [19].
Briefly, isoelectric focusing (IEF) was carried out with
IPG strip gels (Bio-Rad Laboratories) according to the
manufacturer’s instructions at 20 V for 3 h, 500 V for
3 h, 1000 V for 3 h, 4000 V for 3 h, 6000 V for 3 h, and
finally at 8000 V for more than 3 h using an IPGphor
IEF system (Amersham Pharmacia Biotech, Piscataway,
NJ, USA). After IEF, the immobilized pH gradient strips
were equilibrated for 15 min in equilibration buffer
[50 mM Tri-HCl, pH 8.8, 6 M urea, 30% glycerol, 2%
SDS, 2% dithiothreitol (DTT), and 0.002% bromophenol
blue], which was followed by another 15 min incubation
in the same buffer containing 2.5% iodoacetamide in
place of DTT. Next, 2-D SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) was performed on a 12.5%
polyacrylamide gel using a Protein II xi 2-D cell System
(Bio-Rad Laboratories) at 35 mA and 20°C for 6 h. After
electrophoresis, the gel was stained with Coomassie
blue G-250 (Bio-Rad Laboratories) for 16 h and then
destained with distilled water until the background
turned clear. The gel was then analyzed using an Image-
Master 2D-Elite (Amersham Pharmacia Biotech) for
spot detection, quantification, and matching. Differen-
tially expressed spots were analyzed and annotated. The
tryptic peptides produced by the protease digestion
were extracted from the gel plugs by treatment with
0.1% formic acid in 50% ACN. Electrospray ionization
tandem mass spectrometry was performed on the ex-
tracted peptides using a ThermoFinnigan LCQ Deca ion
trap mass spectrometer (Thermo Electron, Mountain
View, CA, USA) coupled with an Agilent 1100 HPLC
system (Agilent Technologies, Inc., Santa Clara, CA,
USA). The acquired collision induced dissociation spectra
were interpreted using TurboSequest software (Thermo-
Finnigan), which matches tandem mass spectra against a
non-redundant protein database.Cell culture
The human hepatoma cell line HepG2 was cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS), 100 units/mL penicillin, 100 mg/mL streptomycin,
0.3 mg/mL L-glutamine and 0.1 mM nonessential amino
acids at 37°C in 5% CO2. The cell culture media and the
fatty acid free FBS were purchased from GIBCO (Carlsbad,
CA, USA). The final concentrations of 80, 100, and
120 μM of each PUFA were diluted by the cell culture
media from 40 mM PUFA stock solution. The fatty
acids media were mixed with fatty acid-free bovine
serum albumin (BSA) stock solution in cell culture
media. The final concentration of BSA was adjusted to
0.012% (w/v) in each PUFA group. After treatment with
PUFAs and cytokines, the cell medium was centrifuged
at 3,000 g for 5 min and the supernatant was collected in
order to determine CRP secretion. The cytosolic protein
was prepared by incubating cells in lysis buffer (10 mM
Tris, pH 7.4/0.32 M sucrose/2 mM 2-mercaptoethanol/
1% Triton X-100/1X protease inhibitor cocktail). The cell
lysates were separated by centrifugation at 12000 g for
20 min at 4°C and stored at −80°C until use.
Cell viability assessment
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was employed to determine the
effect of PUFAs at 80, 100, and 120 μM on cell viability.
Following treatment with PUFAs for 24 h, the cells were
stimulated with IL-1β and IL-6 (10 ng/mL) for an
additional 24 h and then incubated with MTT (0.5% in
PBS) for 4 h at 37°C. The purple formazan crystals
formed were then dissolved in 0.002% Triton X-100/1%
HCl-isopropanol. The extent of MTT reduction was
quantified using a microplate reader at 550 nm and
690 nm. The viability of the samples is expressed rela-
tive to that of control cells (100%).
RT-PCR and real-time quantitative PCR
Total RNA from 1 × 106 cells was extracted with TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). A sample of
1 μg purified RNA was treated with RNase-free DNAse I
(Invitrogen), and then reverse-transcribed with oligo(dT)
primer using the SuperScript First-Strand Synthesis Sys-
tem (Invitrogen) in order to generate cDNA. The PCR
was performed in the buffer containing 10 mM Tris/
HCl, pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 0.2 μM each
dNTP, 1 μM each primer, and 1 unit of ExTAQ DNA
polymerase, and put on a Peltier Thermal Cycler (MJ
Research, Model PTC-200). The sequences of the PCR
primers for the CRP gene amplification were as follows:
forward, 5’-CCTATGTATCCCTCAAAGCA-3’ and re-
verse, 5’-CCCACAGTGTATCCCTCTT-3’. The porpho-
bilinogen deaminase (PBGD) gene was used as an
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lows: forward 5’-AGGATGGGCAACTGTACC-3’ and
reverse 5’-GTTTTGGCTCCTTTGCTCAG-3’. The rela-
tive mRNA levels of CRP were normalized against the
level of PBGD mRNA expression in each assay. Real-time
quantitative PCR was performed with SYBR green master
mixture (Qiagen, Valencia, CA, USA) in a LightCycler
Carousel-Based System (Roche). The primers were used
as follows: CRP: forward, 5’-ACTTCCTATGTATCCCT-
CAAAG-3’ and reverse, 5’-CTCATTGTCTTGTCTCT
TGGT-3’. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH): forward, 5’-GAAGGTGAAGGTCGGAGTC-
3’ and reverse, 5’-GAAGATGGTGATGGGATTTC-3’.
Quantification of CRP mRNA was calculated by the Ct
method (ratio = 2 - (Ct(CRP) - Ct(GAPDH))) as described
previously by Patel et al. [20].
Western blot analysis
The effect of PUFAs on the secretion of CRP into the
cell medium and the STAT3 expression in total cell lys-
ate was determined by western blot analysis. The nuclear
fraction was collected to examine the effects of PUFAs
on IL-6-induced nuclear translocation of STAT3 and
NF-κB subunits p65 and p50. For nuclear protein isola-
tion, cell lysates were incubated in extraction buffer
containing 20 mM HEPES, pH 7.4, 10 mM KCl, 1 mM
MgCl2, 0.5% Nonidet P40, 0.5 mM DTT and complete
protease inhibitor cocktail (Roche, Hercules, CA, USA).
After centrifugation at 3000 g for 10 min, the pellet was
resuspended in cold nuclear extraction buffer [20 mM
HEPES, pH 7.4, 0.4 M NaCl, 10 mM KCl, 1 mM MgCl2,
0.5 mM DTT and 20% (v/v) glycerol supplemented with
complete protease inhibitor cocktail (Roche)]. The pro-
tein concentrations of the cell medium, cell lysates, and
nuclear fractions were determined using the Bradford
assay (Bio-Rad). Equal amounts of proteins were sub-
jected to 10% SDS-PAGE and then transferred onto
polyvinylidene difluoride membrane (Millipore, Billerica,Table 1 Biometric parameters of the control and the experim
Control DHA
BW (g) 26.2 ± 2.8 25.5 ± 2.2
TG (mM) 1.5 ± 0.1 1.1 ± 0.1*
TC (mM) 22 ± 1.8 22.6 ± 1.7
HDL-C (mM) 2.5 ± 0.4 2.6 ± 0.4
LDL-C (mM) 4.2 ± 1.3 4.4 ± 0.9
LW (g) 1.2 ± 0.2 1.3 ± 0.2
HTG (mg/g liver) 95.5 ± 22.2 93.7 ± 14.3
HTC (mg/g liver) 46.1 ± 9.6 42.3 ± 9.8
CN, control; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; AA, arachidon
cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprot
total cholesterol.
*P <0.05 vs. control.MA, USA) after gel electrophoresis. The blots were
blocked with 5% (w/v) skim milk and probed with a
primary antibody and then immunoblotted using a
specific horseradish peroxidase-conjugated secondary
antibody. The blots were stripped for further probing
with albumin, α-tubulin, or B23 antibodies as the in-
ternal controls for medium protein, cytosolic proteins,
or nuclear proteins, respectively. Bound IgG was visual-
ized using an enhanced chemiluminescence detection kit
system (PerkinElmer, Shelton, CT, USA), and quantified
by ImageQuant 5.2 software (Healthcare Bio-Sciences,
Pennsylvania, USA).Transient transfection and reporter assays
Transient transfection was performed using Lipofecta-
mine 2000 reagents (Gibco BRL, Grand Island, NY,
USA) according to the manufacturer’s instructions. The
human CRP promoter fragment from −300/+1 was amp-
lified using the primers 5’-CCGACGCGTACCCAGAT
GGCCACTCGTTTAATATGTTACC-3’ and 5’-CCTAG
ATCTAGAGCTACCTCCTCCTGCCTGG-3’, which con-
tain MluI and BglII restriction sites. The PCR products
were cloned into the luciferase reporter pGL3 basic vector
(Promega), and the DNA sequence was verified by se-
quencing of the clones. HepG2 cells were cotransfected
with 1 μg of CRP promoter-driven luciferase reporter
plasmid and 0.5 μg of pCMV-β-galactosidase expression
plasmid in serum-free DMEM. After 24 h of transfection,
the cells were pretreated with 100 μM PUFAs for 24 h
before stimulation with 10 ng/mL of IL-1β and/or IL-6
for an additional 12 h. Next, the cells were lysed with
lysis buffer (70 mM K2HPO4, 2.1 mM MgCl2, 55 mM
Tris–HCl, pH 7.8, 0.7 mM DTT and 1% Triton X-100)
and the cell lysates were harvested by centrifugation. β-
galactosidase activity was measured by incubating the
cell extracts with o-nitrophenyl-β-D-galactopyranoside
(Sigma-Aldrich, St. Louis, MO, USA). Relative luciferaseental groups
EPA AA LA
25.9 ± 2.8 26.4 ± 2.1 27.4 ± 2.3
1.1 ± 0.1* 1.4 ± 0.3 1.6 ± 0.3
22.4 ± 1.1 23.3 ± 0.9 24.3 ± 1.4*
2.5 ± 0.5 2.7 ± 0.5 3 ± 0.5
4.6 ± 1.2 4.8 ± 1.3 4.9 ± 1.2
1.2 ± 0.1 1.2 ± 0.1 1.3 ± 0.1
90.5 ± 19.5 97.1 ± 17.6 106.6 ± 17.9
43.9 ± 11.7 51.2 ± 11.2 48.1 ± 8.9
ic acid; LA, linoleic acid; BW, body weight; TG, triacylglycerol; TC, total
ein-cholesterol; LW, liver weight; HTG, hepatic triacylglycerol; HTC, hepatic
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ized against the β-galactosidase activity.Statistical analysis
Data are expressed as mean ± SEM of at least three inde-
pendent experiments. Comparisons between control and
experimental groups were made using a one-way ANOVAFigure 1 Representative 2-D gel map of the hepatic proteins in apoE-
in the experimental groups were fed with chow diet plus 200 mg/kg of do
acid (AA), or linoleic acid (LA) in 1.1% ethanol/PBS every day by gavage. Th
pH 5–8 IPG strip as the first dimension and then on a 12.5% SDS-polyacryla
Coomassie blue G-250 and molecular weight standards are shown on the
identities are reported in Table 2.with the Tukey’s method as a post hoc test. P < 0.05 was
considered statistically significant.
Results
Plasma and hepatic lipid levels in response to PUFA
treatment
The mice used in this study remained healthy and were
similar in appearance. No significant difference wasKO mice. Mice were fed a chow diet (control) ad libitum and animals
cosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic
e proteins extracted from the liver were separated initially using a
mide gel as the second dimension. The gels were stained with
left. The differentially modulated protein spots are numbered and their
Table 2 Summary of the regulated proteins present in








D13 Fumarylacetoacetase 3.3 gi|544273
D14 Fructose-1,6-bisphosphatase 1 2.9 gi|14547989
D17 Malate dehydrogenase 2.6 gi|126889
D20 Oxysterols receptor LXR alpha 2.3 gi|12644486
D25 Aldehyde dehydrogenase 2.1 gi|1352250
D26 Isocitrate dehydrogenase 2.1 gi|6647554
D31 SREBP-1 0.5 gi|7144550
D32 Pyruvate carboxylase 0.5 gi|6679237
E8 ATP synthase beta chain 3.1 gi|20455479
E9 Malate dehydrogenase 2.8 gi|126889
E10 Isocitrate dehydrogenase 2.6 gi|6647554
E22 Alpha enolase 2.0 gi|13637776
E23 Fructose-1,6-bisphosphatase 1 2.0 gi|14547989
E24 Pyruvate carboxylase 0.5 gi|6679237
E25 SREBP-1 0.5 gi|7144550
A10 Pyruvate kinase isozyme M2 2.6 gi|2506796




A14 Ketohexokinase 2.1 gi|6016435
L3 Succinyl-CoA synthetase 4.8 gi|52788305
L9 Fructose-1,6-bisphosphatase 1 3.4 gi|14547989
L10 Fumarylacetoacetase 3.2 gi|544273
L14 Phosphoglucomutase 2.8 gi|21362784




D1 Annexin A2 8.2 gi|13435564
D6 Interleukin 1 receptor accessory 4.2 gi|19882203
D9 Peroxiredoxin 6 3.7 gi|6671549
D10 GlutathioneS-transferase, pi1 3.5 gi|10092608
D15 MAP kinase kinase 3 2.9 gi|1771303
D21 A-kinase anchor protein 2.3 gi|2852699
D22 Glutathione S-transferase Mu 5 2.3 gi|1346207
D23 Electron transfer flavoprotein
alpha-subunit
2.2 gi|21759113
D24 DC-SIGN related protein 1 2.2 gi|46395849
D30 Selenium bind protein 2 0.5 gi|9507079
E1 Selenium bind protein 2 6.9 gi|9507079
E6 Peroxiredoxin 6 3.6 gi|3219774
E7 G-protein coupled receptor 3.1 gi|460318
E12 Interleukin 6 receptor, alpha 2.5 gi|7110655
E13 Glutathione S-transferase theta 2 2.4 gi|81916034
Table 2 Summary of the regulated proteins present in
the liver of apoE KO mice treated with different PUFAs
(Continued)
E16 Glucocorticoid-attenuated
response gene 49 protein
2.2 gi|6831574
E18 Peroxiredoxin 4 2.1 gi|3024715
A5 Superoxide dismutase 1, soluble 4.7 gi|45597447
A11 Cyclophilin A 2.3 gi|118105
A20 Selenium bind protein 2 0.5 gi|9507079
L4 Glutathione peroxidase 1 4.7 gi|84871986
L6 Interferon regulatory factor 3.6 gi|972949
L7 Adrenoleukodystrophy protein 3.6 gi|6651050
L8 Glutathione S-transferase Mu 1 3.4 gi|121716
L15 Glutathione transferase omega-1 2.7 gi|6016174
L19 Heat shock protein 60 2.4 gi|51702252
L20 Mitogen-activated protein kinase
10
2.3 gi|2499604
L23 Farnesoid X-activated receptor 2.2 gi|21263825
L25 Peroxiredoxin 4 2.1 gi|3024715
Enzyme
D2 Glycine N-methyltransferase 7.1 gi|6754026
D5 DEAD-box RNA helicase 4.3 gi|6014946










D27 Homogentisate 1,2-oxygenase 2.1 gi|7387755















L12 Caramoyl-phosphate synthase I 2.8 gi|117492




L26 Thiopurine S-methyltransferase 2.0 gi|6094505
Miscellaneous
D3 Hypothetical protein LOC74919 6.8 gi|33563309
D4 Chaperonin groEL precursor 5.4 gi|72957
D11 EF hand domain 3.4 gi|13386360
Huang et al. Journal of Biomedical Science  (2015) 22:12 Page 6 of 14
Table 2 Summary of the regulated proteins present in
the liver of apoE KO mice treated with different PUFAs
(Continued)
D12 Growth-arrest-specific protein 2 3.4 gi|120945
D18 Glial fibrillary acidic protein 2.6 gi|417050
D29 Protein disulfide-isomerase A6
precursor
0.4 gi|2501206







E11 SEC63 2.6 gi|31981948
E14 START domain 2.4 gi|9910482
E15 Growth-arrest-specific protein 2 2.2 gi|120945
E17 Alpha-soluble NSF attachment 2.2 gi|17380315
E19 Beta-actin 2.1 gi|46397316
E21 Selenium bind protein 1 2.1 gi|22164798
A1 Procollagen, type XXIII, alpha 1 9.8 gi|23510253
A2 Advillin 8.3 gi|6857753
A3 Putative TDPOZ1 protein 7.7 gi|38077962
A4 Serum albumin precursor 7.2 gi|5915682
A6 Hypothetical protein LOC225913 4.5 gi|21703976
A7 Growth-arrest-specific protein 2 3.4 gi|120945
A8 Beta-actin 3.1 gi|46397316
A9 START domain 2.8 gi|9910482
A15 Chimerin 1 isoform 2 0.4 gi|13386436
A16 Rab GDP dissociation inhibitor
beta
0.4 gi|1707891
A18 Rho GDP dissociation inhibitor 1 0.4 gi|21759130
L1 Upp2 protein 5.3 gi|20071298
L5 Eukaryotic translation initiation
factor 3 subunit 2
3.9 gi|20138778
L13 Growth-arrest-specific protein 2 2.8 gi|120945
L16 Regucalcin 2.6 gi|2498920




L24 Transducin alpha-1 chain 2.1 gi|121033
L28 Apolipoprotein A-IV precursor 2.0 gi|1703331
(a) The spot numbers correspond to the same protein signal that was
detected in the Figure 1.
(b) The protein names and accession numbers were taken from the
NCBI database.
(c) Ratio of the protein intensity in each PUFA-treated group to the
corresponding spot in the control group represents average values of
triplicate samples.
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of the biochemical parameters (Table 1). However, plasma
levels of triacylglycerol were significantly decreased in theDHA-fed and EPA-fed mice (1.1 ± 0.1 and 1.1 ± 0.1 mM,
respectively) compared to those of the control mice (1.5 ±
0.1 mM). In contrast, plasma total cholesterol levels were
significantly higher in the LA-fed group, while plasma
levels of HDL-cholesterol and LDL-cholesterol were not
statistically different among the five groups. Moreover,
hepatic levels of triacylglycerol and cholesterol in PUFA-
treated mice were also found not to be significantly differ-
ent to those of control mice.Expression of hepatic proteins in the PUFA-treated
apoE-KO mice
A proteomics study was conducted to identify PUFA-
regulated proteins in the liver of apoE-KO mice. Changes
in protein levels were determined by comparison of the
intensities of the corresponding spots on 2-D gels. Figure 1
shows a representative example of the hepatic proteins
separated by 2-D gel electrophoresis. Proteins with pIs
between 5 and 8 and molecular weights ranging from
14 kDa to 165 kDa were resolved. An average of about
700–1100 spots/gel was detected in the area included in
the analysis using the 2-D ImageMaster software on the
Coomassie blue-stained gel. Protein spots were selected
if spot intensities were more than 2-fold increased or
had a ratio value of less than 0.5 compared to their con-
trol counterparts. We utilized at least four replicate 2-D
gels to confirm the presence of significant differences in
spot intensities between the control and the PUFA-
treated mice. The protein identity in the selected spots
was then determined using liquid chromatography-
tandem mass spectrometric analysis. The relative ratios
of the identified proteins are listed in Table 2. Ninety-
three proteins were significantly up-regulated and 12
proteins were remarkably down-regulated by the four
PUFAs. These differentially expressed proteins have
been divided into four categories according to their
major biochemical functions, namely, metabolism, redox
stress/inflammation, enzyme, and other miscellaneous
functions. Table 2 gives a summary of the differentially
expressed proteins for each experimental group com-
pared to the control group. We found that 28, 23, 14,
and 28 proteins were up-regulated in mice treated with
DHA, EPA, AA, and LA, respectively. ApoE-KO mice
treated with DHA, EPA, and LA presented more up-
regulated hepatic proteins. In contrast, 4, 2, 6, and 0
proteins were down-regulated in the DHA, EPA, AA,
and LA groups, respectively. Of the 93 proteins that
were up-regulated in response to PUFA feeding, up to
29 proteins are known to be associated with redox stress
and inflammation. Interestingly, 31 of the 105 PUFA-
regulated proteins are thought to be NF-κB-responsive.
However, their impact and physiological significance
still need to be evaluated.
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expression in HepG2 cells
Taking into account the fact that a large number of the
PUFA-regulated hepatic proteins were greatly associated
with inflammation as shown in Table 2, the mechanisms
of PUFAs on the regulation of inflammatory protein
CRP expression were then elucidated using HepG2 cells.
Initially, HepG2 cells were incubated with various con-
centrations (80, 100, and 120 μM) of PUFAs for 24 h
and were stimulated with 10 ng/mL of IL-1β plus IL-6
for another 24 h. The effect of PUFAs and cytokine on
cell viability was determined by MTT assay. No signifi-
cant toxicity was observed among the cells stimulated by
PUFAs below 120 μM and IL-1β plus IL-6 at the same
time (Figure 2A). Considering that CRP is an inflamma-
tory protein mainly produced by hepatocytes, the regula-
tion of CRP secretion and CRP mRNA expression by
PUFAs were then investigated. Figure 2B shows that
DHA and EPA induced a 52.7% and 56.6% reduction in
CRP secretion, respectively, when compared to the IL-1β
and IL-6-stimulated control group. Furthermore, the IL-Figure 2 Effects of PUFAs on cell viability, CRP secretion, and CRP mR
MTT assay after 24 h of PUFA treatment and after a further 24 h of IL-1β/IL
the control value from cells without PUFA treatment and cytokine challeng
by 100 μM PUFAs for another 24 h. The amount of CRP released into the c
of HepG2 cells with DHA and EPA resulted in an inhibition of CRP mRNA e
(D). Data are expressed as the mean ± SEM of at least three independent e
IL-1β/IL-6-treated cells.1β and IL-6 treatment caused a 15.6-fold increase in
CRP mRNA expression and that DHA and EPA inhib-
ited this induction by more than half (Figure 2C). In
contrast, LA and AA did not have any effect on the regu-
lation of CRP secretion. We also determined the effect of
the PUFAs on CRP mRNA expression by real-time quanti-
tative PCR. As shown in Figure 2D, IL-6-induced CRP
mRNA expression was significantly inhibited by DHA
and EPA, while treatment with LA and AA did not
affect the CRP mRNA expression. All of these results
pointed to the anti-inflammatory role of n-3 PUFAs in
hepatocytes.
Effects of PUFAs on CRP promoter activity
To examine whether the effect of cytokine-induced
CRP gene expression is mediated through transcription
regulation, studies were carried out on HepG2 cells
transiently transfected with a CRP-luciferase construct
that contained the CRP 5’-flanking region consisting
of −300 bp to +1 bp. Under cytokine challenge, IL-6 in-
duced CRP promoter activity by 4.6-fold, but no effectNA expression in HepG2 cells. (A) Cell viability was measured by
-6-stimulation. Cell viability is expressed as a percentage relative to
e. (B) Cells were treated with 10 ng/mL of IL-1β/IL-6 for 24 h followed
ell medium was determined by western blot analysis. Pretreatment
xpression as measured by RT-PCR (C) and real-time quantitative PCR
xperiments, *P < 0.05, **P < 0.01, ***P < 0.001 compared to the
Figure 3 Effects of IL-1β and IL-6 on CRP gene transcription.
HepG2 cells were co-transfected with a CRP promoter reporter
construct and a β–galactosidase construct. After transfection for
24 h, the cells were treated with 10 ng/mL of IL-1β/IL-6 (A), with10
ng/mL of IL-1β alone (B) or with 10 ng/mL of IL-6 alone (C) for an
additional 12 h. The cell lysates were processed and the luciferase
activity was normalized against β-galactosidase activity in order
to correct for transfection efficiency. Relative luciferase units are
indicated as the relative value of the activity of the untreated
group transfected with the pGL3-basic vector (set as 1). Results
are presented as the mean ± SEM of at least three independent
experiments. *P < 0.05 compared to the IL-6-treated group,
**P < 0.01 compared to the vehicle-treated group.
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alone. However, a combination of IL-1β and IL-6 syner-
gistically induced CRP promoter activity by 7.9-fold
(Figure 3A). These results indicate that IL-6 appears to
serve as the major mediator, causing the up-regulation
of CRP gene expression. In addition, IL-1β acts co-
operatively with IL-6 during the induction of CRP pro-
moter activity. Since the findings revealed that IL-1β
and IL-6 affected CRP promoter activity in different
ways, we then investigated whether PUFAs might play
different roles in CRP gene regulation in HepG2 cells
challenged with different cytokines. Luciferase assays
were carried out to explore this hypothesis and showed
that CRP promoter activity was not affected by PUFAs
in cells treated with IL-1β alone (Figure 3B), but that
DHA and EPA reduced the IL-6-induced CRP promoter
activity (Figure 3C). However, LA and AA had no sig-
nificant effect on the regulation of CRP promoter activ-
ity in the IL-6-challenged cells.
Regulation of nuclear p65 and p50 expression by DHA
and EPA
It has been reported that the NF-κB signaling pathway
leads to a series of inflammatory reactions [21]. To
examine whether down-regulation of IL-6-induced hep-
atic CRP expression by DHA and EPA occurs through
the NF-κB signaling pathway, the effect of PUFAs on the
regulation of nuclear p65 and p50 expression was mea-
sured by western blot analysis. As shown in Figure 4A,
DHA remarkably suppressed nuclear NF-κB subunit p65
(also known as RelA) expression, while EPA, LA, and
AA had no effect when compared to the IL-6-stimulated
group. A similar assay was conducted to explore nuclear
p50 expression. Both DHA and EPA were found to in-
hibit nuclear p50 expression in the IL-6-treated cells
(Figure 4B). However, LA and AA did not have any ef-
fect on the regulation of nuclear p50 expression.
Effects of PUFAs on STAT3 activation
Since IL-6 has been reported to enhance STAT3 expres-
sion [22], we then investigated the effect of PUFAs on
Figure 4 Effects of PUFAs on IL-6-induced NF-κB subunit
translocation to the nucleus in HepG2 cells. Cells were pretreated
with 100 μM PUFAs for 24 h before stimulation with 10 ng/mL of IL-6 for
an additional 30 min. The levels of nuclear NF-κB subunits p65 (A) and
p50 (B) were detected by western blot analysis. The expression of
B23 was used as the internal control for the nuclear protein. Data were
quantified by densitometry and the value of the IL-6-treated group was
set as 100%. Results are presented as the mean ± SEM of at least three
independent experiments, **P< 0.01 compared to the IL-6-treated group.
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shown in Figure 5A, the time-course experiments re-
vealed that total and nuclear STAT3 expression was
activated to the greatest degree at 30 min of IL-6 treat-
ment. We found that, although none of the PUFAs
affected the level of STAT3 expression in whole cell ly-
sates (Figure 5B), DHA and EPA displayed a significant
suppressive effect on nuclear STAT3 phosphorylation at
Tyr705 residue (Figure 5C). In contrast, LA and AA did
not have any inhibitory effect on nuclear STAT3 phos-
phorylation. We further examined whether the suppres-
sive effect of DHA and EPA on STAT3 phosphorylation
might occur as a result of the reaction activity of a pro-
tein tyrosine phosphatase (PTPase) in HepG2 cells. We
found that the broad-acting PTPase inhibitor sodium
pervanadate (Na3VO4) was able to remarkably reverse
the suppressive effect of DHA on STAT3 phosphoryl-
ation (Figure 5D), but did not affect the effect of EPA,
LA, and AA (Figure 5D, 5E). These findings suggest
that PTPase activity is involved in the mechanism asso-
ciated with the suppressive effect of DHA on nuclear
STAT3 expression.
Discussion and conclusions
Dietary PUFAs are mostly delivered to the liver [23] and
this organ is an essential metabolic center in animals
and humans. The objective of this study was to investi-
gate the impact of an elevated PUFA status on hepatic
protein expression using an animal model and the regu-
latory mechanisms of CRP expression in PUFA-treated
HepG2 cells. Using a proteomics approach, we pin-
pointed the PUFA-induced changes in the hepatic pro-
tein expression profile. Proteomics is a useful platform
in nutrigenomics as it allows us to determine gene expres-
sion changes in response to diet [24,25]. Furthermore,
proteomics represents a promising tool to uncover the
mechanisms by which nutrients act and to identify the po-
tential of food ingredients with respect to the maintenance
of health or prevention of diseases [26,27]. This work is
the first report to describe the proteome analysis of liver
tissues from apoE-KO mice that have been treated with
different PUFAs.
Our proteomic approach revealed 105 differentially
expressed hepatic proteins in response to the four
PUFAs. Further analysis of the PUFA-regulated proteins
showed that most of the proteins involved in metabol-
ism were up-regulated, though DHA and EPA induced a
decrease in the expression of transcription factor sterol
regulatory element-binding protein-1 (SREBP-1) and
pyruvate carboxylase (PC). SREBP-1 has been proposed
to be a lipogenic transcription factor central to lipogen-
esis and cholesterol metabolism [28] and PC has been
shown to play a role in both glucose and lipid metabol-
ism [29,30]. Thus, one consequence of the suppression
Figure 5 Effects of PUFAs on IL-6-induced STAT3 signaling pathway. (A) Time-dependent effect of IL-6 on STAT3 levels in the nucleus and
total cell lysates was measured by western blot analysis. The expression of B23 and α-tubulin was used as the internal control for the nuclear
protein and cytoplasmic protein, respectively. (B) Immunoblot analysis of whole cell lysates from cells pretreated with 100 μM PUFAs for 24 h and
followed by stimulation with IL-6 for 30 min. (C) Parallel experiments as in panel B, but detecting STAT3 phosphorylation in the nucleus. Data
were quantified by densitometry and the value of the IL-6-treated group was set as 100%. The results are presented as the mean ± SEM of at least
three independent experiments, **P < 0.01 compared to the IL-6-treated group. (D) Cells were treated with IL-6 in absence or presence of the
protein tyrosine phosphatase (PTPase) inhibitor Na3VO4 for 1 h. The effects of DHA and EPA on the phospho-Tyr
705-STAT3 levels in the nucleus
were determined by immunoblot analysis. (E) Parallel experiments similar to those described in panel D, but observing the effect of LA and AA.
The photograph depicts a representative gel from three independent experiments.
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lipogenesis and a disruption of glucose metabolism.
These proteins and their pathways are potential thera-
peutic targets with respect to atherosclerosis and type 2
diabetes [31,32]. In addition, two enzymes (fructose-1,6-
bisphosphatase 1 and alpha enolase), which are respon-
sible for glucose metabolism, and three other enzymes
(malate dehydrogenase, isocitrate dehydrogenase, ATP
synthase), which are responsible for energy metabolism,
are induced more than 2-fold in the n-3 PUFA-treated
animals. Taken together, our proteomics data show thatPUFAs may possibly alter fatty acid oxidation as well as
energy, glucose, and amino acid metabolism.
In addition to the effect of PUFAs on lipid, carbohy-
drate, and energy metabolism, an increased intake of
PUFAs may also lead to enhance oxidative stress [33] or
protect organs against oxidative damage and inflamma-
tion [34]. Among the 105 identified hepatic proteins, 29
proteins were found to be involved in a number of bio-
logical functions associated with redox stress and in-
flammatory processes. Liver is a primary target organ to
relieve oxidative stress, which is considered deleterious
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analysis, it is clear that both DHA and EPA can remark-
ably enhance the hepatic expression of peroxiredoxin 6
(Prdx6), which is a cytoprotective protein that is capable
of reducing the production of hydrogen peroxide [36].
Antioxidant enzymes such as superoxide dismutase 1
and glutathione peroxidase 1 are also induced by AA
and LA, respectively, in the mouse liver. In addition,
increased production of a number of glutathione S-
transferases (GST), which are involved in antioxidant
activity and the detoxification of carcinogens and drugs
[37], were found to be induced in the liver of mice
treated with various PUFAs. Furthermore, a remarkable
increase, 6.9-fold compared with that of the control
group, in the amount of selenium bind protein 2 (SBP2)
was observed in the liver of EPA-treated mice. In con-
trast, SBP2 levels were suppressed in the DHA and AA-
treated groups. These discrepancies may be the result of
the diverse regulatory mechanisms through which dif-
ferent PUFAs act. Further research is needed to extend
our knowledge of PUFA physiological functions.
The association of PUFAs with pro- or anti-
inflammatory functions in liver cells is still not com-
pletely understood. Thus, we focused our studies on
PUFAs that affected the expression of proteins related
to inflammation. Unexpectedly, we found that 13
PUFA-modulated proteins are potentially involved in
pro-inflammation, including annexin A2, interleukin 1
receptor accessory, MAP kinase kinase 3, A-kinase an-
chor protein, DC-SIGN related protein 1, G-protein
coupled receptor (GPCR), interleukin 6 receptor-α, cyclo-
philin A, interferon regulatory factor, adrenoleukodystrophy
protein, glutathione transferase ω-1, heat shock protein 60,Figure 6 Schematic representation of the mechanisms in the regulation
HepG2 cells.and mitogen-activated protein kinase 10. These findings
suggest that increased dietary PUFA supplementation
may enhance inflammatory injury in the liver. A pro-
inflammatory process is known to be a feature of the
complex pro-atherogenic phenotype [38]. However,
much of the interest in fatty acid nutrition has focused
on the role of the n-3 fatty acids as anti-inflammatory pro-
tective agents [12,39], although little attention has yet been
given to the possible role of n-3 fatty acids in the liver.
A close examination of the differentially expressed
proteins from our proteomic analysis showed that a ma-
jority of PUFA-regulated proteins are inflammation re-
lated and associated with the NF-κB signaling pathway.
Increasing evidence suggests that NF-κB is a key tran-
scription factor that modulates the genes responsible
for the immune response and inflammation [21,40].
Dysregulation of the NF-κB pathway plays an essential
role in a number of diseases, including inflammatory
diseases, cancer, and atherosclerosis [41,42]. Based on
these, we extended our investigation to elucidate whether
PUFA treatment affected the NF-κB-signaling pathway in
HepG2 cells.
IL-1 and IL-6 are the two potent inflammation-
associated cytokines that play essential roles in the regu-
lation of immune and inflammatory reactions [43,44]
and can also act as stimulators of CRP production
[45,46]. CRP is synthesized and secreted mainly by the
liver in response to circulating inflammatory mediators
[47]. Elevated CRP levels also serve as a risk marker for
cardiovascular disease, cancer, and mortality [48,49]. Al-
though various roles for CRP in different diseases have
been suggested, little information is available regarding
whether this protein expression is regulated by PUFAsof CRP gene expression by n-3 PUFAs in the IL1β/IL6-challenged
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ways that are triggered by cytokines and investigated
whether CRP gene expression was altered by PUFA
treatment in HepG2 cells.
To our knowledge, this study is the first to offer
insights into the global regulation of hepatic protein ex-
pression in PUFA-treated apoE-KO mice. In the present
study, we elucidate how PUFAs exert their influence on
hepatic metabolism, redox stress/inflammation, enzym-
atic reactions, and miscellaneous functions. We propose
that n-3 PUFAs suppress the cytokine-activated NF-κB
signaling, which would then result in the subsequent
regulation of CRP gene expression in liver cells. Our
data show that DHA suppresses the IL-6-induced trans-
location of nuclear NF-κB subunits p50/p65 heterodi-
mer and p50/p50 homodimer. In contrast, EPA only
inhibits the expression of p50/p50. Furthermore, EPA is
able to inhibit STAT3 activation through suppression of
STAT3 phosphorylation, while DHA suppresses STAT3
activation both through suppression of STAT3 phos-
phorylation and induction of PTPase activity. PTPases
have been known to play as the negative regulators in
STAT3 activation [50]. STAT3 is an acute-phase re-
sponse factor activated by phosphorylation at Tyr705,
such activation leads to IL-6 regulation of many acute-
phase protein genes [51]. Although Janus kinases (JAKs)
pathway may also play as the negative regulator by
cytokine-induce inflammation in different diseases [52],
we mainly focus on the investigation of STAT3 signaling
because that STAT3 is the main mediator of IL-6 induc-
tion in the liver [53]. In the present study, our data show
that DHA and EPA suppress the IL6-induced Tyr705
phosphorylation of STAT3, which in turn inhibit the
transcription activation of CPR gene. In the diagram
presented in Figure 6, we suggest the differential regula-
tory mechanisms whereby DHA and EPA suppress IL-
1/IL-6-induced CRP gene expression.
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